Zeke Capital Advisors LLC acquired a new position in shares of Blueprint Medicines (NASDAQ:BPMC) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 2,253 shares of the biotechnology company’s stock, valued at approximately $207,000.
Several other large investors also recently modified their holdings of the stock. Perceptive Advisors LLC boosted its position in Blueprint Medicines by 168.6% during the fourth quarter. Perceptive Advisors LLC now owns 1,140,434 shares of the biotechnology company’s stock valued at $86,000,000 after purchasing an additional 715,773 shares in the last quarter. TimesSquare Capital Management LLC raised its position in Blueprint Medicines by 27.4% in the fourth quarter. TimesSquare Capital Management LLC now owns 1,105,230 shares of the biotechnology company’s stock valued at $83,345,000 after purchasing an additional 237,530 shares during the period. OppenheimerFunds Inc. raised its position in Blueprint Medicines by 8.4% in the fourth quarter. OppenheimerFunds Inc. now owns 1,632,006 shares of the biotechnology company’s stock valued at $123,070,000 after purchasing an additional 126,752 shares during the period. Artal Group S.A. purchased a new stake in Blueprint Medicines in the fourth quarter valued at $7,541,000. Finally, BlackRock Inc. raised its position in Blueprint Medicines by 3.3% in the fourth quarter. BlackRock Inc. now owns 3,081,861 shares of the biotechnology company’s stock valued at $232,401,000 after purchasing an additional 98,581 shares during the period. Institutional investors and hedge funds own 97.41% of the company’s stock.
A number of equities research analysts have commented on BPMC shares. Zacks Investment Research downgraded Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday, May 7th. BidaskClub upgraded Blueprint Medicines from a “hold” rating to a “buy” rating in a report on Monday, April 16th. ValuEngine upgraded Blueprint Medicines from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Cowen reiterated a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, February 21st. Finally, Wedbush boosted their price objective on Blueprint Medicines from $98.00 to $106.00 and gave the company an “outperform” rating in a report on Monday, April 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Blueprint Medicines has an average rating of “Buy” and an average target price of $87.80.
In other news, Director George Demetri sold 5,492 shares of the company’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $100.09, for a total transaction of $549,694.28. Following the completion of the transaction, the director now directly owns 10,231 shares of the company’s stock, valued at approximately $1,024,020.79. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $92.57, for a total value of $1,851,400.00. Following the transaction, the chief executive officer now directly owns 20,000 shares of the company’s stock, valued at $1,851,400. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,792 shares of company stock worth $6,406,505. 3.40% of the stock is owned by company insiders.
Blueprint Medicines traded up $0.17, hitting $82.07, during trading hours on Friday, according to Marketbeat Ratings. 337,716 shares of the company were exchanged, compared to its average volume of 549,008. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.40 and a quick ratio of 15.40. Blueprint Medicines has a 52-week low of $34.38 and a 52-week high of $109.00. The company has a market cap of $3.59 billion, a price-to-earnings ratio of -20.94 and a beta of 1.00.
Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported ($1.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by ($0.23). Blueprint Medicines had a negative return on equity of 37.00% and a negative net margin of 1,068.27%. The company had revenue of $0.95 million for the quarter, compared to analysts’ expectations of $2.82 million. During the same quarter last year, the company earned ($0.84) EPS. Blueprint Medicines’s revenue for the quarter was down 83.7% compared to the same quarter last year. equities research analysts anticipate that Blueprint Medicines will post -5.39 earnings per share for the current fiscal year.
Blueprint Medicines Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.